HYDRODISTENSION PLUS BOTULINUM TOXIN IN REFRACTORY BLADDER PAIN SYNDROME

Hypothesis / aims of study
Bladder pain syndrome (BPS) is a disease of unknown etiology with a complex treatment. When conservative management fails, European guidelines suggest to carry out, under general anesthesia, hydrodistension plus botulinum toxin, as an effective option.

Study design, materials and methods
We performed a retrospective study of 21 patients with refractory BPS, who underwent bladder hydrodistension plus 100 U of botulinum toxin in trigone, between 2012 and 2014. In all, 27 procedures (21 first procedures and 6 relapses) were performed. In order to assess the pain improvement we used: TBS and PGIC, EVA score and BPICC-SS questionnaire. Moreover, we evaluated the degree of change in micturition frequency with a three day bladder diary. We used Wilcoxon and Kruskal-Wallis tests for the data analysis. Finally, we assessed how long the improvement lasted by means of a Kaplan-Meier curve.

Results
In 21 of 27 procedures (85%), the patients described that their pain had improved (3 slightly, 9 mildly and 21 strongly). EVA score decreased strongly one month after the procedure, with a statistically significant difference (p:0.022). We also observed a decrease in diurnal and nocturnal micturition frequency, but without a statistically significant difference (p:0.589 and p:0.074, respectively). On the other hand, the observed improvement was seen both in first procedures and in successive ones. These results were independent of age and previous cystoscopic findings. The median duration of pain relief was 6 months (IC95%: 3.7-8.3).

Interpretation of results
Hydrodistension plus botulinum toxin can be considered as an effective treatment in refractory patients which can be performed every six months since the effectiveness in relapses cases is similar to that obtained in primary cases.

Concluding message
Bladder hydrodistension under general anesthesia plus botulinum toxin injection is a suitable treatment in refractory BPS.

References

Disclosures
Funding: None Clinical Trial: No Subjects: HUMAN Ethics not Req’d: Because this is a retrospective study Helsinki: Yes Informed Consent: Yes